BGNE BeiGene Ltd.

85.14
+0.25  (0%)
Previous Close 84.89
Open 84.98
Price To book 15.10
Market Cap 3862739648
Shares 45,369,270
Volume 230,623
Short Ratio 5.88
Av. Daily Volume 246,631

SEC filingsSee all SEC filings

  1. 8-K - Current report 171079329
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 171064438
  3. 8-K - Current report 171064258
  4. 8-K - Current report 171041251
  5. UPLOAD [Cover] - SEC-generated letter

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 preliminary data presented at ESMO 2017 - ORR 33%.
BGB-290
Solid tumors - cancer
Phase 2 pivotial China trial initiation announced July 5, 2017.
BGB-A317
Urothelial cancer (UC) - bladder cancer
Phase 2 pivotal China trial initiation announced April 21, 2017.
BGB-A317
Hodgkin lymphoma
Phase 1/2 preliminary data presented at ESMO 2017.
BGB-A317
Solid tumors
Phase 3 dosing of China based trial announced March 2, 2017.
BGB-3111
Relapsed or refractory mantle cell lymphoma (MCL)
Phase 3 trial initiation announced January 25, 2017.
BGB-3111
Waldenström’s macroglobulinemia

Latest News

  1. BeiGene Announces Presentation at the 20th Annual Meeting of the Chinese Society of Clinical Oncology
  2. These 3 Biotech Stocks Just Hit 52-Week Highs: Are They Buys?
  3. [$$] Celgene Launch to Lift BeiGene
  4. BeiGene Presents Preliminary Phase 1 Data for BGB-A317 in Multiple Solid Tumors at the ESMO 2017 Congress
  5. BeiGene Presents Preliminary Phase 1/2 Clinical Data on PARP Inhibitor BGB-290 in Patients with Advanced Solid Tumors at the European Society for Medical Oncology 2017 Congress
  6. BeiGene Announces Closing of Global Strategic Oncology Collaboration with Celgene Corporation
  7. BeiGene Announces Presentations at the European Society for Medical Oncology 2017 Congress
  8. BeiGene to Present at Upcoming Investor Conferences
  9. BeiGene Announces Pricing of $175 Million Public Offering
  10. BeiGene Announces Proposed Public Offering
  11. BeiGene Reports Second Quarter 2017 Financial Results
  12. How Celgene Performed in 2Q17
  13. Why BeiGene Soared 56.6% In July
  14. These 3 Stocks Have Doubled Investors' Money in 2017
  15. Biotech Stock Roundup: Arena Shoots Up on Study Data, CELG Inks Immuno-Oncology Deal
  16. [$$] BeiGene Boosted by Celgene Deal
  17. Why Celgene's $413 Million Gamble Helps This Small Biotech More
  18. Celgene (CELG), BeiGene Team Up For PD-1 Inhibitor in China
  19. Celgene Enters PD1 Market with BeiGene Deal
  20. Why HSN, Herman Miller, and BeiGene Jumped Today

SEC Filings

  1. 8-K - Current report 171079329
  2. SC 13G - Statement of acquisition of beneficial ownership by individuals 171064438
  3. 8-K - Current report 171064258
  4. 8-K - Current report 171041251
  5. UPLOAD [Cover] - SEC-generated letter
  6. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171029944
  7. 8-K - Current report 171025400
  8. 424B5 - Prospectus [Rule 424(b)(5)] 171025125
  9. 424B5 - Prospectus [Rule 424(b)(5)] 171019351
  10. 8-K - Current report 171019336